Variable | Patients with Complete Remission (CR) N (%) | Patients with Relapsed Disease (RD) N (%) |
---|---|---|
Number | 96 | 34 |
Age at diagnosis | Â | Â |
Median | 31 | 27.5 |
15-20 | 16 (16.7) | 17 (50) |
21-30 | 32 (33.3) | 5 (14.7) |
31-40 | 18 (18.8) | 5 (14.7) |
> 40 | 30 (31.2) | 8 (20.6) |
Gender | Â | Â |
Males | 50 (52.1) | 21 (61.8) |
Females | 46 (47.9) | 13 (38.2) |
Stage | Â | Â |
Early stages (I &II) | 41 (42.7) | 20 (58.8) |
Advanced stages (III & IV) | 38 (39.6) | 12 (35.3) |
Missed data | 17 (17.7) | 2 (5.9) |
Presence of B symptoms | Â | Â |
Yes | 54 (56.3) | 19 (55.9) |
No | 31 (32.3) | 13 (38.2) |
Missed data | 11 (11.4) | 2 (5.9) |
Bone marrow involvement | Â | Â |
Yes | 5 (5.2) | 4 (11.8) |
No | 91 (94.8) | 30 (88.2) |
Histology | Â | Â |
Nodular sclerosis | 46 (47.9) | 16 (47.1) |
Mixed cellularity | 25 (26) | 6 (17.6) |
Lymphocyte rich | 5 (5.2) | 3 (8.8) |
Lymphocyte depleted | 4 (4.2) | 0 (0) |
Nodular lymphocyte predominance | 1 (1) | 5 (14.7) |
Classical | 7 (7.3) | 4 (11.8) |
Missed data | 8 (8.3) | - |
Chemotherapy regimen | ABVD: All the patients | ABVD: Initially all the patients at relapse: ICEa (8), ESHAPb (8), COPPc (3), ABVDd (8), Others: (7). |
Number of ABVD cycles | Â | Â |
< 6 cycles | 10 (10.4) | 6 (17.6) |
6 cycles | 77 (80.2) | 22 (64.7) |
> 6 cycles | 9 (9.4) | 5 (14.7) |